The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†

Abstract

These findings suggest that long-term therapy with pioglitazone may be necessary to maintain improvements in disease activity in patients with NASH, although weight gain during treatment may ultimately limit its beneficial effects.